

November 13, 2025

BSE LimitedP J Towers,
Dalal Street,
Mumbai – 400 001**National Stock Exchange of India Limited**Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051**Scrip Code: 543904****Symbol: MANKIND**

Dear Sir/ Madam,

Subject: Disclosure regarding withdrawal and outstanding Credit Rating**Ref.: Regulation 30 & 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

Pursuant to Regulations 30 and 51 of the Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that ICRA Limited, on the request of the Company, vide its letter dated November 13, 2025 has withdrawn the credit rating for the following instrument of the Company:

Instrument	Amount (₹ crore)	Rating	Rating Action
Commercial Paper	3,500	(ICRA) A1+	Withdrawn

Other outstanding ratings are as follows:

Instrument	Amount (₹ crore)	Rating	Rating Action
Non-Convertible Debentures	5,000	(ICRA) AA+/Stable	Outstanding
Commercial Paper	1,500	(ICRA) A1+	Outstanding
Long-term/Short term fund based limits	1,250	(ICRA)AA+ (Stable)/ (ICRA)A1+	Outstanding

The above information will also be available on the website of the Company at www.mankindpharma.com.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited****Hitesh Kumar Jain**
Company Secretary &
Compliance Officer**MANKIND PHARMA LIMITED**Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com